ABUS Arbutus Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABUS

Price (delayed)

$3

Market cap

$487.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$459.12M

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
The company's EPS rose by 45% YoY and by 4.2% QoQ
The debt has declined by 16% year-on-year and by 6% since the previous quarter
ABUS's quick ratio has shrunk by 68% YoY and by 9% QoQ
Arbutus Biopharma's equity has decreased by 19% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arbutusbio.com
Peers: NRC NWBO

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
162.57M
Market cap
$487.71M
Enterprise value
$459.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.43
Price to sales (P/S)
11.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.77
Earnings
Revenue
$39.02M
EBIT
-$63.29M
EBITDA
-$61.86M
Free cash flow
-$35.87M
Per share
EPS
-$0.46
Free cash flow per share
-$0.24
Book value per share
$0.87
Revenue per share
$0.26
TBVPS
$1.29
Balance sheet
Total assets
$195.42M
Total liabilities
$58.57M
Debt
$2.19M
Equity
$136.85M
Working capital
$118.28M
Liquidity
Debt to equity
0.02
Current ratio
4.6
Quick ratio
4.51
Net debt/EBITDA
0.46
Margins
EBITDA margin
-158.5%
Gross margin
100%
Net margin
-178%
Operating margin
-162%
Efficiency
Return on assets
-32.6%
Return on equity
-46.2%
Return on invested capital
-45.6%
Return on capital employed
-38.9%
Return on sales
-162.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-0.99%
1 week
-0.99%
1 month
8.7%
1 year
-1.64%
YTD
28.76%
QTD
28.76%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$39.02M
Gross profit
$39.02M
Operating income
-$63.22M
Net income
-$69.46M
Gross margin
100%
Net margin
-178%
ABUS's operating margin has surged by 75% year-on-year and by 7% since the previous quarter
The net margin has surged by 74% year-on-year and by 7% since the previous quarter
The company's operating income rose by 12% YoY
Arbutus Biopharma's net income has increased by 9% YoY

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
3.43
P/S
11.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.77
The company's EPS rose by 45% YoY and by 4.2% QoQ
ABUS's price to book (P/B) is 65% higher than its 5-year quarterly average of 2.1 and 38% higher than its last 4 quarters average of 2.5
Arbutus Biopharma's equity has decreased by 19% YoY and by 6% QoQ
The price to sales (P/S) is 60% lower than the 5-year quarterly average of 29.3 and 5% lower than the last 4 quarters average of 12.4
Arbutus Biopharma's revenue has increased by 8% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 76% YoY and by 7% QoQ
The ROIC rose by 49% year-on-year and by 7% since the previous quarter
Arbutus Biopharma's return on assets has increased by 40% YoY
The ROE is up by 33% year-on-year but it is down by 5% since the previous quarter

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
ABUS's quick ratio has shrunk by 68% YoY and by 9% QoQ
The company's current ratio has shrunk by 68% YoY and by 10% QoQ
The debt is 98% smaller than the equity
Arbutus Biopharma's equity has decreased by 19% YoY and by 6% QoQ
The debt has declined by 16% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.